Oct 20 (Reuters) - NanoViricides Inc NNVC.A:
NANOVIRICIDES: CLINICAL LEAD DRUG NV-387 HAS SHOWN STRONG ACTIVITY AGAINST MEASLES VIRUS IN A HUMANIZED ANIMAL MODEL
NANOVIRICIDES: NV-387 CAN NOW BE MADE AVAILABLE FOR EMERGENCY USE APPLICATION IN MEASLES PATIENTS TO RESPOND TO SPREADING MEASLES OUTBREAKS
NANOVIRICIDES: NV-387 HAS ALREADY COMPLETED PHASE I CLINICAL TRIAL IN HEALTHY SUBJECTS WITH NO REPORTED ADVERSE EVENTS
Further company coverage: NNVC.A
((((Reuters.Briefs@thomsonreuters.com));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.